Zhang Xiaoshu, Wang Yue, Cao Yanning, Zhang Xueshan, Zhao Haiya
Department of Immunology, Binzhou Medical University, Yantai, 264003, China.
Oncotarget. 2017 May 18;8(43):73817-73825. doi: 10.18632/oncotarget.17982. eCollection 2017 Sep 26.
Cervical cancer is the third most common cancer and the fourth leading cause of malignancy related mortality in women worldwide. CCL19 is highly expressed in human cancer cells, and ligand CCL19 binding to CCR7 induces actin polymerization and pseudopodia formation. However, whether or not CCL19 is involved in EMT of human cervical cancer needs further investigation. Using quantitative PCR and western blot analyses, we found that CCL19 is overexpressed in cervical cancer cell lines and tissues. Knockdown of CCL19 via siRNA inhibited the proliferation of cervical cancer cells by increasing apoptosis. Further analyses showed that inhibitory effects of CCL19 on cell migration and invasion were partly associated with EMT process. In conclusion, these data indicate that CCL19 is abnormally expressed in cervical cancer, indicating a novel and important role for CCL19 in cervical cancer malignant transformation.
宫颈癌是全球女性中第三常见的癌症，也是恶性肿瘤相关死亡的第四大主要原因。CCL19在人类癌细胞中高度表达，配体CCL19与CCR7结合会诱导肌动蛋白聚合和伪足形成。然而，CCL19是否参与人类宫颈癌的上皮-间质转化（EMT）仍需进一步研究。通过定量PCR和蛋白质印迹分析，我们发现CCL19在宫颈癌细胞系和组织中过表达。通过小干扰RNA（siRNA）敲低CCL19可通过增加细胞凋亡来抑制宫颈癌细胞的增殖。进一步分析表明，CCL19对细胞迁移和侵袭的抑制作用部分与EMT过程有关。总之，这些数据表明CCL19在宫颈癌中异常表达，表明CCL19在宫颈癌恶性转化中具有新的重要作用。
